Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA inspected Goa...

    USFDA inspected Goa facility, no observations issued: Indoco Remedies

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-30T11:52:20+05:30  |  Updated On 13 Aug 2021 4:35 PM IST

    The US Food and Drug Administration (USFDA) has cleared the Goa-based sterile manufacturing facility of Indoco Remedies for finished dosages.


    New Delhi: Drug firm Indoco Remedies Friday said the US health regulator has cleared its Goa-based manufacturing facility after concluding an inspection. The US Food and Drug Administration (USFDA) has cleared the Goa-based sterile manufacturing facility of the company for finished dosages, Indoco Remedies said in a regulatory filing.


    The health regulator had inspected the plant in November last year, it added.


    Medical Dialogues had earlier reported that the firm Indoco had received two minor observations from the US health regulator for its Goa-based two plants. The US Food and Drug Administration (USFDA) had inspected Indoco's Sterile facility (Plant II) and Solid Dosages facility (Plant III) situated at L-32/33/34 Verna Industrial Estate, Goa from 14th November till 21st November 2018. The inspection concluded with Indoco receiving 2 minor observations, none of which are a repeat in nature.


    The facility had received a Warning Letter from the USFDA in March 2017.


    Also Read: Indoco Remedies gets two minor observations from USFDA for Goa plants


    Currently, in a regulatory filing the company said, "The change in the inspection classification status from 'Official Action Initiated' (OAI) to 'Voluntary Action Initiated' for Indoco Remedies by USFDA signifies that the site has come out of the warning letter issued to the site in March 2017."


    Several pending abbreviated new drug applications (ANDAs) from this facility will now be approved, it added.


    Indoco Remedies is headquartered in Mumbai. In 1945, a Goan entrepreneur Mr Govind Ramnath Kare, who was in the business of wholesale and retail trade of pharmaceuticals, started a firm which he named Indo Continental Trading Company. The principal business of this firm was to import pharmaceutical formulations from Europe and distribute them in Western India.


    However in 1947, after India became independent, the new Government in its bid to encourage indigenous manufacturing of medicines banned the import of several formulations. Mr G.R. Kare instead of being discouraged decided to venture into manufacturing of pharmaceuticals.


    Accordingly, on 23rd August 1947, a week after India's independence, a new Company was founded with the intent to manufacture and sell pharmaceutical formulations.


    Thus, Indo Continental Trading Company became Indoco Remedies Limited.




    Also Read: Indoco Remedies Q4 net profit down 14 pc at Rs 18 crore



    aditi kare panandikarANDABSEDrug firmEIRGoahealthhealth carehealth regulatorHealthcare NewsIndocoindoco goa plantIndoco Remediesindoco sterile faciltyinspectionmedicalmedical newsonservationpharmapharma newspharma news indiasterilesterile manufacturing facilityUS health regulatorUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok